Masahiro TORASAWA, MD. PhD.· @M_Torasawa · X·· 23 小时前评分70
正文 · 机器翻译
#ESMO26 LBA3
🚨 DeLLphi-305：III 期 ES-SCLC 结果！
Tarlatamab + durvalumab 对比 durvalumab 作为 1L 维持治疗 (n=563)
✅ OS：21.1 对 12.7 个月 (HR 0.42)
✅ PFS：7.4 对 1.9 个月 (HR 0.34)
✅ ORR：26.4% 对 4.1%
⚠️ CRS：49.6%（G≥3：0.4%）
⚠️ ICANS：1.1%
令人印象深刻的生存获益！有望成为新的标准治疗。
335 浏览 · 6 赞 · 0 转发 · 1 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org1/4 🔥 #ESMO26 Lung Cancer Presidential Highlights 🇪🇸 Madrid | October 24–25, 2026 Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms: 🎙️ LBA3 | DeLLphi-305 🎙️ LBA5 | KRASCENDO 1 🎙️ LBA6 | SAFFRON Three Phase 3 readouts to watch closely at #ESMO26 👀 @myESMO @OncoAlert @Larvol在 X 查看被引用的帖子
帖内回复
- Mustafa Özdoğan, MD@ozdogan_md
@M_Torasawa Clear numbers. One frame I'll watch at PS I: OS gain (HR 0.42; +8.4 mo median) vs CRS burden (49.6%, G≥3 rare). Was ICANS systematically captured in both arms?
来源：Masahiro TORASAWA, MD. PhD. · x.com